@article{ed5bed137011496fbd401ae6a07441ab,
title = "Rebuttal From Dr Shifren et al",
author = "Adrian Shifren and Alex Chen and Mario Castro",
note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts: Dr Castro has received university grant monies (each >$100,000) from the National Institutes of Health, Centers for Disease Control and Prevention, and ALA and pharmaceutical company grant monies (each >$100,000) from Asthmatx, which developed and markets the Alair Bronchial Thermoplasty System discussed in this article, Amgen, Cephalon, Centocor, GlaxoSmithKline, Genentech, Medimmune, Merck, Novartis, and Pfizer. Dr Castro has received consultancy fees ($10,001-$50,000) from Asthmatx, advisory board fees ($5,001-$10,000) from Genentech, and royalties from Elsevier. Dr Castro has been a consultant for Genentech and participated in speaking activities for AstraZeneca, Boeringer-Ingelheim, Genentech, Merck, and Pfizer. Drs Shifren and Chen report that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).",
year = "2011",
month = sep,
doi = "10.1378/chest.11-1411",
language = "English",
volume = "140",
pages = "577--578",
journal = "CHEST",
issn = "0012-3692",
number = "3",
}